Tirzepatide (Mounjaro/Zepbound)
Type 2 Diabetes
About Eli Lilly
Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.
View full company profileAbout Eli Lilly
Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |